Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | PI4KA | P42356 | 3/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.41 |
| ▸ | NSD2 | O96028 | 4/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096596 | 0.83 | ADORA2A (0.58) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4094997 | 0.82 | ADORA2A (0.61) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4094994 | 0.81 | ADORA2A (0.56) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10389962 | 0.79 | SRC (0.38) | EGFR | |
| SCHEMBL11294401 | 0.77 | HPRT1 (0.35) | SMN1; SMN2 | |
| SCHEMBL16397567 | 0.76 | CYP3A4 (0.61) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23516234 | 0.75 | CYP3A4 (0.53) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10518103 | 0.74 | ADORA2A (0.58) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8846480 | 0.73 | ADORA2A (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10514725 | 0.73 | ADORA2A (0.54) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | ADORA2A 1461/4885PI4KA 3172/4885PI4K2B 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.